Show simple item record

dc.contributor.authorTo, Kendricken
dc.contributor.authorZhang, Bridgeten
dc.contributor.authorRomain, Karlen
dc.contributor.authorMak, Christopheren
dc.contributor.authorKhan, Wasimen
dc.date.accessioned2019-10-30T00:30:54Z
dc.date.available2019-10-30T00:30:54Z
dc.date.issued2019-01en
dc.identifier.issn2296-4185
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/298208
dc.description.abstractArticular cartilage damaged through trauma or disease has a limited ability to repair. Untreated, focal lesions progress to generalized changes including osteoarthritis. Musculoskeletal disorders including osteoarthritis are the most significant contributor to disability globally. There is increasing interest in the use of mesenchymal stem cells (MSCs) for the treatment of focal chondral lesions. There is some evidence to suggest that the tissue type from which MSCs are harvested play a role in determining their ability to regenerate cartilage in vitro and in vivo. In humans, MSCs derived from synovial tissue may have superior chondrogenic potential. We carried out a systematic literature review on the effectiveness of synovium-derived MSCs (sMSCs) in cartilage regeneration in in vivo studies in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. Twenty studies were included in our review; four examined the use of human sMSCs and sixteen were conducted using sMSCs harvested from animals. Most studies reported successful cartilage repair with sMSC transplantation despite the variability of animals, cell harvesting techniques, methods of delivery and outcome measures. We conclude that sMSC transplantation holds promise as a treatment option for focal cartilage defects. We believe that defining the cell population being used, establishing standardized methods for MSC delivery, and the use of objective outcome measures should enable future high quality studies such as randomized controlled clinical trials to provide the evidence needed to manage chondral lesions optimally.
dc.description.sponsorshipThe authors gratefully acknowledge the financial support of Versus Arthritis (Formerly Arthritis Research UK) through Versus Arthritis Tissue Engineering & Regenerative Therapies Centre (Grant 21156).
dc.format.mediumElectronic-eCollectionen
dc.languageengen
dc.publisherFrontiers Research Foundation
dc.rightsAll rights reserved
dc.rights.uri
dc.titleSynovium-Derived Mesenchymal Stem Cell Transplantation in Cartilage Regeneration: A PRISMA Review of in vivo Studies.en
dc.typeArticle
prism.publicationDate2019en
prism.publicationNameFrontiers in bioengineering and biotechnologyen
prism.startingPage314
prism.volume7en
dc.identifier.doi10.17863/CAM.45260
dcterms.dateAccepted2019-10-23en
rioxxterms.versionofrecord10.3389/fbioe.2019.00314en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2019-01en
dc.contributor.orcidKhan, Wasim [0000-0003-3106-5424]
dc.identifier.eissn2296-4185
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idARTHRITIS RESEARCH UK (21156)
rioxxterms.freetoread.startdate2022-10-29


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record